What is SiSaf?
SiSaf Ltd is a biopharmaceutical firm headquartered in Guildford, England, specializing in the development of RNA therapeutics for cancer and musculoskeletal disorders. The company's core innovation lies in its proprietary Bio-Courier technology, a unique combination of bioabsorbable silicon and organic materials designed to optimize the delivery of nucleic acids. This advanced delivery system enables SiSaf to pursue a pipeline of novel treatments targeting conditions such as pancreatic cancer, metastatic cancer, and osteopetrosis. The company operates state-of-the-art research and manufacturing facilities, positioning it for advanced therapeutic development.
How much funding has SiSaf raised?
SiSaf has raised a total of $16.7M across 2 funding rounds:
Series A
$3.5M
Series B
$13.2M
Series A (2016): $3.5M with participation from Exen Capital and Vickers Venture Partners
Series B (2020): $13.2M led by Future Fund and Vickers Venture Partners
Key Investors in SiSaf
Future Fund
Future Fund is an Australian investment fund established to invest for the benefit of future generations, focusing on easing government financial pressures through strategic superannuation liabilities.
Vickers Venture Partners
Vickers Venture Partners is a global venture capital firm specializing in deep tech investments worldwide, with a history of backing successful technology companies and offices in key international hubs.
Exen Capital
Exen Capital is an investment firm with a presence in New York, Dallas, and London, focusing on strategic investments including venture capital, private equity, and real estate, alongside yield strategies.
What's next for SiSaf?
The recent major strategic investment in SiSaf signals a critical growth phase, likely enabling the company to accelerate its research and development efforts, expand its clinical trial programs, and scale its manufacturing capabilities. This substantial capital infusion, part of its $16.7M in total funding, will be instrumental in advancing its RNA therapeutic pipeline, particularly for oncology and rare bone diseases. The backing from strategic investors suggests confidence in SiSaf's Bio-Courier technology and its potential to disrupt current treatment paradigms. Future developments will likely focus on progressing existing candidates through regulatory pathways and potentially exploring new therapeutic applications for their platform.
See full SiSaf company page
